ClinicalTrials.gg
RecruitingNCT07890454Updated Nov 13, 2026

Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

A Phase 3 interventional study of IIV-HD (standalone) and NVXC19 (EU licensed, standalone) in Immunization, Healthy Volunteers and COVID-19 Immunization, sponsored by Sanofi. Recruiting at 2 sites in Poland. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Updated Nov 13, 2026Now RecruitingFirst site in Poland+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,000
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Planned enrollment
5th of 126
6,000 · median 305
Started
2026
with 4 others
Phase 3
35 of 139
1 open now
Registered
139th of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 5th largest by planned enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2026, is one of 35 in phase 3, and was the 139th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.

Study details include:

  • The study duration will be approximately 12 months per participant
  • Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01
03

Conditions studied

  • Immunization
  • Healthy Volunteers
  • COVID-19 Immunization
  • Influenza Immunization

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria

Inclusion criteria to be checked at Screening Visit:

  • Aged 60 years or older on the day of inclusion
  • form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
  • Aged 60 years or older on the day of inclusion
  • Participants who are healthy or with pre-existing stable condition, as determined by medical evaluation including medical history and physical examination
  • Non- (i.e., for at least 1 year or surgically sterile)
  • lnformed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine

Exclusion criteria Exclusion Criteria to be Checked at Screening Visit and at Visit 1 (D01) Medical conditions

  • Known/suspected immunodeficiency; therapy in past 6 months; long-term systemic
  • Known systemic to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
  • Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • History of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
  • Personal or family history of Guillain-Barré syndrome
  • Prior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
  • Any vaccine given within 4 weeks before or within 4 weeks after study intervention
  • Previous vaccination against influenza (in the previous 6 months before study intervention) with an or marketed vaccine OR history of influenza infection in the previous 6 months
  • Previous vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
  • Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
  • Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
  • Is an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
6,000 participants (estimated)

Study arms

  • Active comparator
    Group 1, IIV-HD and EU-licensed NVXC19

    IIV-HD and NVXC19 co-administered in opposite deltoid muscles

    Drug: IIV-HD (standalone) · Drug: NVXC19 (EU licensed, standalone)

  • Experimental
    Group 2, IIV-HD + NVXC19 combination and placebo

    IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles

    Drug: IIV-HD + NVXC19 combination · Drug: Placebo, normal saline

Interventions

  • DrugIIV-HD (standalone)

    Pharmaceutical form: Suspension Route of administration: Intramuscular injection

  • DrugNVXC19 (EU licensed, standalone)

    Pharmaceutical form: Dispersion Route of administration: Intramuscular injection

  • DrugIIV-HD + NVXC19 combination

    Pharmaceutical form: Suspension Route of administration: Intramuscular injection

  • DrugPlacebo, normal saline

    Pharmaceutical form: Solution Route of administration: Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Antibody titers against for each of the 3 influenza vaccine strains(in a subset of participants)

    Geometric mean (GMT) of antibody titers measured by hemagglutination inhibition (HAI)

    Time frame: At Day 28 after vaccination

  2. Antibody titers against SARS-CoV-2 specific variant(in a subset of participants)

    Geometric mean (GMT) of antibody titers measured by pseudovirus neutralization test (PNT)

    Time frame: At Day 28 after vaccination

Secondary outcomes

  1. Presence of solicited injection site reactions for 8 days, including the day of vaccination (Main subset of participants)

    Number of participants with solicited injection site reactions pre-listed in the participant diary and case report form (CRF)

    Time frame: Up to 8 each days after vaccination

  2. Presence of solicited systemic reactions for 8 days, including the day of vaccination (Main subset of participants)

    Number of participants with solicited systemic reactions pre-listed in the participant diary and case report form (CRF)

    Time frame: Up to 8 each days after vaccination

  3. Presence of immediate adverse events after vaccination

    Number of participants with immediate adverse events (AEs). Immediate adverse events are any unsolicited systemic adverse events within 30 minutes after vaccination

    Time frame: Within the 30 minutes after vaccination

  4. Presence of unsolicited adverse events

    Number of participants with unsolicited adverse events (AEs) for 28 days, including the day of vaccination

    Time frame: Up to 28 days after vaccination

  5. Presence of all medically attended adverse events

    Number of participants with medical attended adverse events (MAAEs) for 180 days, including the day of vaccination

    Time frame: Up to 180 days after vaccination

  6. Presence of related medically attended adverse events linked to predefined potential immune-mediated diseases

    Number of participants with medical attended adverse events (MAAEs) linked to predefined potential immune-mediated diseases (PIMDs) following the study vaccination

    Time frame: From Day 181 through 12 months following study vaccination

  7. Presence of all adverse events of special interest

    Number of participants with adverse events of special interest (AESIs) for 180 days, including the day of vaccination

    Time frame: Up to 180 days after vaccination

  8. Presence of all serious adverse events

    Number of participants with serious adverse events (SAEs) for 180 days, including the day of vaccination

    Time frame: Up to 180 days after vaccination

  9. Presence of related serious adverse events

    Number of participants with serious adverse events (SAEs) from D181 through 12 months following the last study vaccination

    Time frame: From Day 181 through 12 months following study vaccination

  10. Presence of related adverse events of special interest

    Number of participants with adverse events of special interest (AESIs) from D181 through 12 months following the last study vaccination

    Time frame: From Day 181 through 12 months following study vaccination

  11. Presence of related medical attended adverse events linked to predefined potential immune-mediated diseases that meet the criteria for serious adverse events

    Number of patients with medical attended adverse events (MAAES) linked to predefined potential immune-mediated diseases (PIMDs) meets criteria for serious adverse events (SAEs) from D181 through 12 months following the last study vaccination

    Time frame: From Day 181 through 12 months following study vaccination

  12. Presence of adverse events leading to study discontinuation throughout the study

    Number of participants with adverse events lead to study discontinuation

    Time frame: From Day 01 through 12 months

  13. Influenza seroconversion status after vaccination for each of the 3 influenza vaccine strains

    Percentage of participants Seroconversion is defined by: pre-injection antibody titer \< 10 \[1/dil\] at D01 and post-injection antibody titer ≥ 40 \[1/dil\] at D29, or pre-injection antibody titer ≥ 10 \[1/dil\] at D01 and a ≥ 4-fold increase in titer at D29

    Time frame: At Day 29

  14. SARS-CoV-2 seroresponse status after vaccination

    Percentage of participantsSeroresponse to SARS-CoV-2 is defined by: pre-injection antibody titer \< LLOQ \[1/dil\] and post-injection antibody titer ≥ 4\*LLOQ \[1/dil\] at D29, or pre-injection antibody titer ≥ LLOQ \[1/dil\] at D01 and a ≥ 4-fold increase in titer \[1/dil\] at D29

    Time frame: At Day 29

  15. Neutralizing antibody titers measured by neutralization test (NT) against each of the 3 influenza vaccine strains before and after vaccination (in a subset of participants)

    Neutralizing antibody titers \[1/dil\]

    Time frame: At Day 01 and Day 29

  16. Individual neutralizing antibody titer ratio measured by neutralization test NT against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)

    Individual neutralizing titers ratio Day 29/Day 01

    Time frame: At Day 01 and Day 29

  17. Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination(in a subset of participants)

    Percentage of participants with neutralization test (NT) titer ≥ 10 (1/dil)

    Time frame: At Day 29

  18. Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)

    Percentage of participants with neutralization test (NT) titer ≥ 20 (1/dil)

    Time frame: At Day 29

  19. Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)

    Percentage of participants with neutralization test (NT) titer ≥ 40 (1/dil)

    Time frame: At Day 29

  20. Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)

    Percentage of participants with neutralization test (NT) titer ≥ 80 (1/dil)

    Time frame: At Day 29

  21. Fold increase in neutralization test antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)

    Percentage of participants fold increase is defined in neutralization test (NT) antibody titer \[post/pre\] ≥ 2-fold rise from Day 01 to Day 29

    Time frame: At Day 29

  22. Fold increase in neutralization test antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)

    Percentage of participants fold increase is defined in neutralization test (NT) antibody titer \[post/pre\] ≥ 4-fold rise from Day 01 to Day 29

    Time frame: At Day 29

07

Study locations

2 of 2 sites recruiting
  • Investigational Site Number : 6160002
    Wroclaw, Lower Silesian Voivodeship 50-088, Poland
    Recruiting
  • Investigational Site Number : 6160020
    Gdynia, Pomeranian Voivodeship 81-384, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 14 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2026
First posted
Oct 22, 2026
StartActual
Oct 28, 2026was Nov 2026
Primary completionEst.
Dec 28, 2027
CompletionEst.
Dec 28, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
2 sites added — first site in Poland
Show 2 added (2 Poland)
  • Investigational Site Number : 6160002 · Wroclaw, Poland
  • Investigational Site Number : 6160020 · Gdynia, Poland
Nov 13, 2026
Start date
Nov 9, 2026→Oct 28, 2026 (actual)
Nov 13, 2026
Eligibility
5 criteria edited, 16 added
What changed in the criteria
  • AddedInclusion criteria
  • EditedInclusion Criteria: Inclusion criteria to be checked at Screening Visit:
  • EditedParticipant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
  • EditedInformedlnformed consent form has been signed and dated
  • EditedInclusionExclusion criteria Exclusion Criteria to be checkedChecked at Screening Visit and at Visit 1 (D01) Medical conditions
  • AddedKnown/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
  • AddedKnown systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
  • AddedSelf-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
  • AddedBleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
  • AddedChronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • AddedModerate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved.
  • AddedAlcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • AddedHistory of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
  • AddedPersonal or family history of Guillain-Barré syndrome
  • AddedPrior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
  • AddedAny vaccine given within 4 weeks before or within 4 weeks after study intervention
  • AddedPrevious vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
  • AddedPrevious vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
  • AddedHas received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
  • AddedDeprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
  • EditedIs an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a patientparticipant's potential participation in a clinical trial.
Nov 13, 2026
Registered
First appeared on the registry
Oct 22, 2026
Show all 2 updates
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Poland
    Show 2 added (2 Poland)
    • Investigational Site Number : 6160002 · Wroclaw, Poland
    • Investigational Site Number : 6160020 · Gdynia, Poland
    Start date Nov 9, 2026→Oct 28, 2026 (now actual)
    Eligibility 5 criteria edited, 16 added
    What changed in the criteria
    • AddedInclusion criteria
    • EditedInclusion Criteria: Inclusion criteria to be checked at Screening Visit:
    • EditedParticipant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
    • EditedInformedlnformed consent form has been signed and dated
    • EditedInclusionExclusion criteria Exclusion Criteria to be checkedChecked at Screening Visit and at Visit 1 (D01) Medical conditions
    • AddedKnown/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
    • AddedKnown systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
    • AddedSelf-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
    • AddedBleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
    • AddedChronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
    • AddedModerate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved.
    • AddedAlcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
    • AddedHistory of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
    • AddedPersonal or family history of Guillain-Barré syndrome
    • AddedPrior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
    • AddedAny vaccine given within 4 weeks before or within 4 weeks after study intervention
    • AddedPrevious vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
    • AddedPrevious vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
    • AddedHas received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
    • AddedDeprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
    • EditedIs an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a patientparticipant's potential participation in a clinical trial.
    + 3 other changes: verification date, description and design details
  2. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07890454
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 28, 2026
Primary completion
Dec 28, 2027 (estimated)
Completion
Dec 28, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion